A Strategy for Measuring the Therapeutic Properties of New Antiparkinsonian Drugs, such as + PHNO, in Patients with On-Off Fluctuations

Abstract
Summary We describe a simple quantitative bedside method for assessing the dopaminergic properties of new therapeutic agents, namely, by documenting their duration of action in patients with Parkinson's disease who exhibit “on-off' fluctuations. This model represents a form of human dopaminergic “bioassay”.